- Home
- OI vs RCKT Comparison
OI vs RCKT Comparison
Compare OI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OI
- RCKT
- Stock Information
- Founded
- OI 1903
- RCKT 1999
- Country
- OI United States
- RCKT United States
- Employees
- OI N/A
- RCKT N/A
- Industry
- OI Containers/Packaging
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- OI Consumer Discretionary
- RCKT Health Care
- Exchange
- OI Nasdaq
- RCKT Nasdaq
- Market Cap
- OI 2.2B
- RCKT 264.0M
- IPO Year
- OI N/A
- RCKT N/A
- Fundamental
- Price
- OI $15.41
- RCKT $2.99
- Analyst Decision
- OI Buy
- RCKT Buy
- Analyst Count
- OI 8
- RCKT 13
- Target Price
- OI $17.13
- RCKT $18.50
- AVG Volume (30 Days)
- OI 1.9M
- RCKT 3.8M
- Earning Date
- OI 07-29-2025
- RCKT 08-04-2025
- Dividend Yield
- OI N/A
- RCKT N/A
- EPS Growth
- OI N/A
- RCKT N/A
- EPS
- OI N/A
- RCKT N/A
- Revenue
- OI $6,505,000,000.00
- RCKT N/A
- Revenue This Year
- OI $2.05
- RCKT N/A
- Revenue Next Year
- OI $1.35
- RCKT N/A
- P/E Ratio
- OI N/A
- RCKT N/A
- Revenue Growth
- OI N/A
- RCKT N/A
- 52 Week Low
- OI $9.23
- RCKT $2.19
- 52 Week High
- OI $16.04
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- OI 62.49
- RCKT 45.55
- Support Level
- OI $15.07
- RCKT $2.76
- Resistance Level
- OI $15.88
- RCKT $3.24
- Average True Range (ATR)
- OI 0.47
- RCKT 0.19
- MACD
- OI 0.01
- RCKT 0.17
- Stochastic Oscillator
- OI 69.62
- RCKT 74.85
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.